MedTrace Logo

Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.

NCT07532707 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-04-16

No results posted yet for this study

Summary

This study compares the clinical effectiveness of Intravenous Immunoglobulin (IVIG) versus Plasma Exchange (PLEX) in patients experiencing a myasthenic crisis. Clinical response is evaluated 14 days post-treatment using the Quantitative Myasthenia Gravis Score (QMG). Additionally, the study aims to identify and report common precipitating factors for myasthenic attacks, such as respiratory infections or surgical stress.

Conditions

  • Myasthenic Crisis
  • Myasthenia Gravis (MG)

Interventions

BIOLOGICAL

IVIG (Intravenous Immunoglobulin)

Patients receive Intravenous Immunoglobulin (IVIG) at a total dose of 2 g/kg body weight. The dose is divided over a period of 2 to 5 consecutive days administered intravenously

PROCEDURE

Plasma exchange (PE)

Patients undergo therapeutic plasma exchange (PLEX), typically consisting of 5 sessions performed every other day., with a replacement volume of 1 to 1.5 plasma volumes per session.

Sponsors & Collaborators

  • Al Mouwasat Hospital

    collaborator OTHER

  • Al-Assad University Hospital

    collaborator OTHER

  • Damascus University

    lead OTHER

Principal Investigators

  • Mohammad Shehadeh Agha, MD, PhD · Damascus University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-10-15
Completion
2023-10-30

Countries

  • Syria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07532707 on ClinicalTrials.gov